Structure–Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2
Molecules · 2024
DOI: 10.3390/molecules30010063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Lukas Kröger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany. Hauptthemen laut MEDLINE: Casein Kinase II, Carbazoles, Protein Kinase Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, discount voucher ba8c87d23218af92 (100.00%).
Abstract (Originalsprache)
The serine/threonine kinase CK2 (formerly known as casein kinase II) plays a crucial role in various CNS disorders and is highly expressed in various types of cancer. Therefore, inhibiting this key kinase could be promising for the treatment of these diseases. The CK2 holoenzyme is formed by the recruitment of two catalytically active CK2α and/or CK2α′ subunits by a regulatory CK2β dimer. Starting with the lead furocarbazole W16 (4) inhibiting the CK2α/CK2β interaction, analogous pyrrolocarbazoles were prepared and tested for their protein–protein interaction inhibition (PPII). The key step of the synthesis was a multicomponent Levy reaction of 2-(indolyl)acetate 6, benzaldehydes 7, and N-substituted maleimides 8. Targeted modifications were performed by the saponification of the tetracyclic ester 9a, followed by the coupling of the resulting acid 10 with diverse amines. The replacement of the O-atom of the lead furocarbazole 4 by an N-atom in pyrrolocarbazoles retained or even increased the inhibition of the CK2α/CK2β interaction. The large benzyloxazolidinyl moiety of 4 could be replaced by smaller N-substituents without the loss of the PPII. The introduction of larger substituents at the 2-position and/or at p-position of the phenyl moiety at the 10-position to increase the surface for the inhibition of the PPI did not enhance the inhibition of the CK2α/CK2β association. The strong inhibition of the CK2α/CK2β association by the histidine derivative (+)-20a (Ki = 6.1 µM) translated into a high inhibition of the kinase activity of the CK2 holoenzyme (CK2α2β2, IC50 = 2.5 µM). Thus, 20a represents a novel lead compound inhibiting CK2 via the inhibition of the association of the CK2α and Ck2β subunits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany.
- Institutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, D-50931 Cologne, Germany.
- Faculty of Applied Natural Sciences, TH Köln-University of Applied Sciences, Campus Leverkusen, Campusplatz 1, D-51379 Leverkusen, Germany.
ORCID-Profile: Sebastian Borgert, Miriam Lauwers, Joachim Jose, Markus Pietsch, Bernhard Wünsch
Förderung
- Deutsche Forschungsgemeinschaft
- discount voucher ba8c87d23218af92 (100.00%)
Zitieren
APA
Kröger, L., Borgert, S., Lauwers, M., Steinkrüger, M., Jose, J., Pietsch, M., & Wünsch, B. (2024). Structure–Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2. Molecules. https://doi.org/10.3390/molecules30010063
Vancouver
Kröger L, Borgert S, Lauwers M, Steinkrüger M, Jose J, Pietsch M, et al. Structure–Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2. Molecules. 2024. doi:10.3390/molecules30010063
BibTeX
@article{Krger2024,
author = {Kröger, Lukas and Borgert, Sebastian and Lauwers, Miriam and Steinkrüger, Michaela and Jose, Joachim and Pietsch, Markus and Wünsch, Bernhard},
title = {Structure–Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules30010063}
}
EUVIMED